Reviews
24 November 2020

Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing?: A Systematic Review

Publication: Annals of Internal Medicine
Volume 174, Number 3

Abstract

Background:

Financial payments from the drug industry to U.S. physicians are common. Payments may influence physicians' clinical decision making and drug prescribing.

Purpose:

To evaluate whether receipt of payments from the drug industry is associated with physician prescribing practices.

Data Sources:

MEDLINE (Ovid), Embase, the Cochrane Library, Web of Science, and EconLit were searched without language restrictions. The search had no limiting start date and concluded on 16 September 2020.

Study Selection:

Studies that estimated the association between receipt of industry payments (exposure) and prescribing (outcome).

Data Extraction:

Pairs of reviewers extracted the primary analysis or analyses from each study and evaluated risk of bias (ROB).

Data Synthesis:

Thirty-six studies comprising 101 analyses were included. Most studies (n = 30) identified a positive association between payments and prescribing in all analyses; the remainder (n = 6) had a mix of positive and null findings. No study had only null findings. Of 101 individual analyses, 89 identified a positive association. Payments were associated with increased prescribing of the paying company's drug, increased prescribing costs, and increased prescribing of branded drugs. Nine studies assessed and found evidence of a temporal association; 25 assessed and found evidence of a dose–response relationship.

Limitation:

The design was observational, 21 of 36 studies had serious ROB, and publication bias was possible.

Conclusion:

The association between industry payments and physician prescribing was consistent across all studies that have evaluated this association. Findings regarding a temporal association and dose-response suggest a causal relationship.

Primary Funding Source:

National Cancer Institute.

Get full access to this article

View all available purchase options and get full access to this article.

Supplemental Material

Supplement. Supplementary Material

References

1.
Inoue KBlumenthal DMElashoff Det al. Association between physician characteristics and payments from industry in 2015-2017: observational study. BMJ Open. 2019;9:e031010. [PMID: 31542759]  doi: 10.1136/bmjopen-2019-031010
2.
Mitchell AP, Mishra AA, Dey P, et al. The association between drug industry payments and NCCN guideline panel membership [Abstract]. J Clin Oncol. 2020;38(Suppl):2068. 2020 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 4–8 June 2020. Abstract no. 2068. doi: 10.1200/JCO.2020.38.15_suppl.2068
3.
Robbins NMMeyer MJBernat JL. Scope and nature of financial conflicts of interest between neurologists and industry: 2013-2016. Neurology. 2019;93:438-449. [PMID: 31383793]  doi: 10.1212/WNL.0000000000008067
4.
Schlager EFlaten HSt Claire Cet al. Industry payments to dermatologists: updates from the 2016 Open Payment data. Dermatol Online J. 2018;24. [PMID: 29906014]
5.
Elsamadicy AAFreedman IGKoo ABet al. Characteristics of reported industry payments to neurosurgeons: a 5-year Open Payments Database study. World Neurosurg. 2020. [PMID: 33011357]  doi: 10.1016/j.wneu.2020.09.137
6.
Centers for Medicare & Medicaid Services. The facts about Open Payments data: 2018 totals. Accessed at https://openpaymentsdata.cms.gov/summary on 28 March 2020.
7.
Schwartz LMWoloshin S. Medical marketing in the United States, 1997-2016. JAMA. 2019;321:80-96. [PMID: 30620375]  doi: 10.1001/jama.2018.19320
8.
Brennan TARothman DJBlank Let al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295:429-33. [PMID: 16434633]
9.
Lichter AS. Conflict of interest and the integrity of the medical profession. JAMA. 2017;317:1725-1726. [PMID: 28464163]  doi: 10.1001/jama.2017.3191
10.
Mitchell APBasch EMDusetzina SB. Financial relationships with industry among National Comprehensive Cancer Network guideline authors. JAMA Oncol. 2016;2:1628-1631. [PMID: 27561170]  doi: 10.1001/jamaoncol.2016.2710
11.
Carr DWelch HG. Industry payments to physician directors of National Cancer Institute–designated cancer centers, 2015-2017. JAMA Intern Med. 2019. [PMID: 31380888]  doi: 10.1001/jamainternmed.2019.3098
12.
Gill JHaslam ACrain Tet al. Comparison of industry payments in 2017 with annual salary in a cohort of academic oncologists. JAMA Intern Med. 2020;180:797-799. [PMID: 32202604]  doi: 10.1001/jamainternmed.2020.0090
13.
Samuel AMWebb MLLukasiewicz AMet al. Orthopaedic surgeons receive the most industry payments to physicians but large disparities are seen in Sunshine Act data. Clin Orthop Relat Res. 2015;473:3297-306. [PMID: 26088767]  doi: 10.1007/s11999-015-4413-8
14.
Tringale KRMarshall DMackey TKet al. Types and distribution of payments from industry to physicians in 2015. JAMA. 2017;317:1774-1784. [PMID: 28464140]  doi: 10.1001/jama.2017.3091
15.
Oldani MJ. Thick prescriptions: toward an interpretation of pharmaceutical sales practices. Med Anthropol Q. 2004;18:325-56. [PMID: 15484967]
16.
Sah SFugh-Berman A. Physicians under the influence: social psychology and industry marketing strategies. J Law Med Ethics. 2013;41:665-72. [PMID: 24088157]  doi: 10.1111/jlme.12076
17.
Brax HFadlallah RAl-Khaled Let al. Association between physicians' interaction with pharmaceutical companies and their clinical practices: a systematic review and meta-analysis. PLoS One. 2017;12:e0175493. [PMID: 28406971]  doi: 10.1371/journal.pone.0175493
18.
Davari MKhorasani ETigabu BM. Factors influencing prescribing decisions of physicians: a review. Ethiop J Health Sci. 2018;28:795-804. [PMID: 30607097]  doi: 10.4314/ejhs.v28i6.15
19.
Fickweiler FFickweiler WUrbach E. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review. BMJ Open. 2017;7:e016408. [PMID: 28963287]  doi: 10.1136/bmjopen-2017-016408
20.
Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? CMAJ. 1993;149:1401-7. [PMID: 8221424]
21.
Spurling GKMansfield PRMontgomery BDet al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med. 2010;7:e1000352. [PMID: 20976098]  doi: 10.1371/journal.pmed.1000352
22.
Higgins JP, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions. 6th ed. Cochrane; 2019. Accessed at www.training.cochrane.org/handbook on 23 June 2020.
23.
McGowan JSampson MSalzwedel DMet al. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40-6. [PMID: 27005575]  doi: 10.1016/j.jclinepi.2016.01.021
24.
Bramer WMGiustini Dde Jonge GBet al. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104:240-3. [PMID: 27366130]  doi: 10.3163/1536-5050.104.3.014
25.
Sterne JAHernán MAReeves BCet al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. [PMID: 27733354]  doi: 10.1136/bmj.i4919
26.
Parker-Lue S. The impact of reducing pharmaceutical industry payments on physician prescribing. Health Econ. 2020;29:382-390. [PMID: 31930636]  doi: 10.1002/hec.3993
27.
Bandari JTurner RM 2ndJacobs BLet al. The relationship of industry payments to prescribing behavior: a study of degarelix and denosumab. Urol Pract. 2017;4:14-20. [PMID: 28149927]  doi: 10.1016/j.urpr.2016.03.007
28.
Murrin S. Open Payments data: review of accuracy, precision, and consistency in reporting. Department of Health and Human Services Office of the Inspector General; 2018. Report no. OEI-03-15-00220. Accessed at https://oig.hhs.gov/oei/reports/oei-03-15-00220.pdf on 26 September 2019.
29.
Ratain MJ. Forecasting unanticipated consequences of “the Sunshine Act”: mostly cloudy. J Clin Oncol. 2014;32:2293-5. [PMID: 24934789]  doi: 10.1200/JCO.2014.55.4592
30.
Fleischman WAgrawal SGross CPet al. Association of pharmaceutical manufacturer payments to physicians and prescribing dosage of opioids [Letter]. J Gen Intern Med. 2019;34:1074-1076. [PMID: 31011967]  doi: 10.1007/s11606-019-04897-9
31.
Carey C, Lieber EMJ, Miller S. Drug firms' payments and physicians' prescribing behavior in Medicare Part D. National Bureau of Economic Research. February 2020. Accessed at www.nber.org/papers/w26751.pdf on 27 March 2020.
32.
Agha L, Zeltzer D. Drug diffusion through peer networks: the influence of industry payments. October 2019. Accessed at www.nber.org/papers/w26338 on 28 September 2020.
33.
Brunt CS. Physician characteristics, industry transfers, and pharmaceutical prescribing: empirical evidence from Medicare and the Physician Payment Sunshine Act. Health Serv Res. 2019;54:636-649. [PMID: 30273976]  doi: 10.1111/1475-6773.13064
34.
Mitchell APWinn ANDusetzina SB. Pharmaceutical industry payments and oncologists' selection of targeted cancer therapies in Medicare beneficiaries. JAMA Intern Med. 2018;178:854-856. [PMID: 29630687]  doi: 10.1001/jamainternmed.2018.0776
35.
Hartung DMJohnston KCohen DMet al. Industry payments to physician specialists who prescribe repository corticotropin. JAMA Netw Open. 2018;1:e180482. [PMID: 30646086]  doi: 10.1001/jamanetworkopen.2018.0482
36.
Modi PKWang YKirk PSet al. The receipt of industry payments is associated with prescribing promoted alpha-blockers and overactive bladder medications. Urology. 2018;117:50-56. [PMID: 29680480]  doi: 10.1016/j.urology.2018.04.008
37.
Qian JHansen RASurry Det al. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing. Pharmacoepidemiol Drug Saf. 2017;26:819-826. [PMID: 28485111]  doi: 10.1002/pds.4224
38.
DeJong CAguilar TTseng CWet al. Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Intern Med. 2016;176:1114-1122. [PMID: 27322350]  doi: 10.1001/jamainternmed.2016.2765
39.
Hadland SECerdá MLi Yet al. Association of pharmaceutical industry marketing of opioid products to physicians with subsequent opioid prescribing. JAMA Intern Med. 2018;178:861-863. [PMID: 29799955]  doi: 10.1001/jamainternmed.2018.1999
40.
Khan RNugent CMScaffidi MAet al. Association of biologic prescribing for inflammatory bowel disease with industry payments to physicians. JAMA Intern Med. 2019. [PMID: 31282918]  doi: 10.1001/jamainternmed.2019.0999
41.
Mehta HBMoore TJAlexander GC. Association of pharmaceutical industry payments to physicians with prescription and Medicare expenditures for pimavanserin. Psychiatr Serv. 2020:appips202000251. [PMID: 32838675]  doi: 10.1176/appi.ps.202000251
42.
Mitchell APWinn ANLund JLet al. Evaluating the strength of the association between industry payments and prescribing practices in oncology. Oncologist. 2019;24:632-639. [PMID: 30728276]  doi: 10.1634/theoncologist.2018-0423
43.
Orlowski JPWateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest. 1992;102:270-3. [PMID: 1623766]
44.
Morse EHanna JMehra S. The association between industry payments and brand-name prescriptions in otolaryngologists. Otolaryngol Head Neck Surg. 2019;161:605-612. [PMID: 31547772]  doi: 10.1177/0194599819852321
45.
Zezza MABachhuber MA. Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing. PLoS One. 2018;13:e0209383. [PMID: 30566426]  doi: 10.1371/journal.pone.0209383
46.
Hollander MAGDonohue JMStein BDet al. Association between opioid prescribing in Medicare and pharmaceutical company gifts by physician specialty. J Gen Intern Med. 2020;35:2451-2458. [PMID: 31792860]  doi: 10.1007/s11606-019-05470-0
47.
Inoue KFigueroa JFOrav EJet al. Association between industry payments for opioid products and physicians' prescription of opioids: observational study with propensity-score matching. J Epidemiol Community Health. 2020;74:647-654. [PMID: 32350126]  doi: 10.1136/jech-2020-214021
48.
Chren MMLandefeld CS. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271:684-9. [PMID: 8309031]
49.
Hayes MJPrasad V. Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma. J Cancer Policy. 2019;21:100189.  doi: 10.1016/j.jcpo.2019.100189
50.
Lundh ALexchin JMintzes Bet al. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;2:MR000033. [PMID: 28207928]  doi: 10.1002/14651858.MR000033.pub3
51.
Peppercorn JBlood EWiner Eet al. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer. 2007;109:1239-46. [PMID: 17326054]
52.
Liang FZhu JMo Met al. Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication. Ann Oncol. 2018;29:2129-2134. [PMID: 30084933]  doi: 10.1093/annonc/mdy305
53.
Tibau ABedard PLSrikanthan Aet al. Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. J Clin Oncol. 2015;33:100-6. [PMID: 25385736]  doi: 10.1200/JCO.2014.57.8898
54.
Greenway TRoss JS. US drug marketing: how does promotion correspond with health value? BMJ. 2017;357:j1855. [PMID: 28465309]  doi: 10.1136/bmj.j1855
55.
Lexchin J. The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis. CMAJ Open. 2017;5:E724-E728. [PMID: 28912143]  doi: 10.9778/cmajo.20170089
56.
Mahr MAHodge DOErie JC. Association between industry payments and anti-vascular endothelial growth factor use in Medicare beneficiaries. Ophthalmol Retina. 2017;1:19-24. [PMID: 31047391]  doi: 10.1016/j.oret.2016.08.001
57.
Morse EFujiwara RJTMehra S. The association of industry payments to physicians with prescription of brand-name intranasal corticosteroids. Otolaryngol Head Neck Surg. 2018;159:442-448. [PMID: 29865931]  doi: 10.1177/0194599818774739
58.
Morse EFujiwara RJTMehra S. Industry payments to physicians and prescriptions of brand-name proton-pump inhibitors. Otolaryngol Head Neck Surg. 2019;160:70-76. [PMID: 30325706]  doi: 10.1177/0194599818803337
59.
Rhee TGRoss JS. Association between industry payments to physicians and gabapentinoid prescribing. JAMA Intern Med. 2019. [PMID: 31282922]  doi: 10.1001/jamainternmed.2019.1082
60.
Sharma MVadhariya AJohnson MLet al. Association between industry payments and prescribing costly medications: an observational study using open payments and Medicare Part D data. BMC Health Serv Res. 2018;18:236. [PMID: 29609611]  doi: 10.1186/s12913-018-3043-8
61.
Singh PForman HAdamson ASet al. Impact of industry payments on prescribing patterns for tumor necrosis factor inhibitors among Medicare beneficiaries. J Gen Intern Med. 2019;34:176-178. [PMID: 30324292]  doi: 10.1007/s11606-018-4698-x
62.
Singh NChang JSRachitskaya AV. Open Payments database: anti-vascular endothelial growth factor agent payments to ophthalmologists. Am J Ophthalmol. 2017;173:91-97. [PMID: 27697472]  doi: 10.1016/j.ajo.2016.09.026
63.
Taylor SCHuecker JBGordon MOet al. Physician-industry interactions and anti-vascular endothelial growth factor use among US ophthalmologists. JAMA Ophthalmol. 2016;134:897-903. [PMID: 27356110]  doi: 10.1001/jamaophthalmol.2016.1678
64.
Goupil BBalusson FNaudet Fet al. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases. BMJ. 2019;367:l6015. [PMID: 31690553]  doi: 10.1136/bmj.l6015
65.
Carrier M, Shadowen S. Pharmaceutical product hopping: a proposed framework for antitrust analysis. Health Affairs Blog. 1 June 2017. Accessed at www.healthaffairs.org/do/10.1377/hblog20170601.060360/full on 30 June 2020.
66.
Cole ALWood WA JrMuluneh Bet al. Comparative safety and health care expenditures among patients with chronic myeloid leukemia initiating first-line imatinib, dasatinib, or nilotinib. JCO Oncol Pract. 2020;16:e443-e455. [PMID: 32196424]  doi: 10.1200/JOP.19.00301
67.
Treat S. Responses of Rep. Sharon Treat to questions from Senator Kohl. In: Paid to Prescribe? Exploring the Relationship Between Doctors and the Drug Industry. Special Committee on Aging, United States Senate. Serial no. 110-10. US Gov Pr Office; 2007:128-31.
68.
Korenstein DKeyhani SRoss JS. Physician attitudes toward industry: a view across the specialties. Arch Surg. 2010;145:570-7. [PMID: 20566978]  doi: 10.1001/archsurg.2010.75
69.
Fischer MAKeough MEBaril JLet al. Prescribers and pharmaceutical representatives: why are we still meeting? J Gen Intern Med. 2009;24:795-801. [PMID: 19424764]  doi: 10.1007/s11606-009-0989-6
70.
Brett ASBurr WMoloo J. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians. Arch Intern Med. 2003;163:2213-8. [PMID: 14557219]
71.
Halperin ECHutchison PBarrier RC Jr. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. Int J Radiat Oncol Biol Phys. 2004;59:1477-83. [PMID: 15275735]
72.
Cain DMDetsky AS. Everyone's a little bit biased (even physicians). JAMA. 2008;299:2893-5. [PMID: 18577735]  doi: 10.1001/jama.299.24.2893
73.
Altawalbeh SMIbrahim IAAl-Shatnawi SF. Influence of pharmaceutical promotion on prescribers in Jordan. Int J Clin Pharm. 2020;42:744-755. [PMID: 32140917]  doi: 10.1007/s11096-020-01006-3
74.
Annapureddy A, Minges KE, Henien S, et al. Association between industry payments to physicians and device selection: a report from the NCDR ICD registry [Abstract]. Circulation. 2018;138(Suppl 1). 2018 American Heart Association Scientific Sessions, Chicago, Illinois, 10–14 November 2018. Abstract no. 14982.
75.
Ayyash OM, Bandari J, Turner RM II, et al. The relationship of physician payments from drug manufacturers to Medicare claims for abiraterone and enzalutamide [Abstract]. Can Urol Assoc J. 2016;10(Suppl 4):S183. Northeastern Section of the American Urological Association 68th Annual Meeting, Buffalo, New York, 29 September–1 October 2016. Abstract no. P64.
76.
Ayyash O, Bandari J, Turner R, et al. Small effect of pharmaceutical industry payments to physicians on Medicare prescription habits: using abiraterone and enzalutamide [Abstract]. J Urol. 2017;197(Suppl):e1013. American Association of Urology Annual Meeting, Boston, Massachusetts, 12–16 May 2017. Abstract no. MP76-03. doi: 10.1016/j.juro.2017.02.2131
77.
Bandari J, Turner RM II, Jacobs BL, et al. An analysis of industry effects on prescriber behavior: degarelix and denosumab [Abstract]. Can Urol Assoc J. 2016;10(Suppl 4):S179-80. Northeastern Section of the American Urological Association 68th Annual Meeting, Buffalo, New York, 29 September–1 October 2016. Abstract no. P54.
78.
Berger JT. Pharmaceutical industry influences on physician prescribing: gifts, quasi-gifts, and patient-directed gifts. Am J Bioeth. 2003;3:56-7. [PMID: 14594495]
79.
Bourdette D, Van Leuvin S, Johnston K, et al. Industry payments to neurologists who commonly prescribe repository corticotropin gel (H.P. Acthar) [Abstract]. Neurology. 2017;88(Suppl):P3.400. American Academy of Neurology 69th Annual Meeting, Boston, Massachusetts, 22–28 April 2017.
80.
Carlat D. Exploring the link between industry payments to doctors and prescribing habits. BMJ. 2014;349:g6651. [PMID: 25378357]  doi: 10.1136/bmj.g6651
81.
Catricalà A. International non-proprietary name (INN) prescribing and conflict of interest. Article in Italian. Ricerca & Pratica. 2007;23:37-8.  doi: 10.1707/238.2822
82.
Chua K, Li G, Stahl P, et al. Are industry payments for tadalafil associated with prescribing habits among urologists and primary care physicians? [Abstract]. J Urol. 2019;201(Suppl):e383. American Association of Urology Annual Meeting, Chicago, Illinois, 3–6 May 2019. Abstract no. PD21-03. doi: 10.1097/01.JU.0000555747.05854.c6
83.
Duarte-Garcia A, Crowson CS, McCoy R, et al. Association between payments by pharmaceutical manufacturers and prescribing behavior in rheumatology [Abstract]. Arthritis Rheumatol. 2018;70(Suppl):3379-80. 2018 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting, Chicago, Illinois, 19–24 October 2018. Abstract no. 2997.
84.
Dyer O. Industry payments to doctors drive surge in gabapentinoid prescribing, study finds. BMJ. 2019;366:l4672. [PMID: 31300395]  doi: 10.1136/bmj.l4672
85.
Eisenberg MDStone EMPittell Het al. The impact of academic medical center policies restricting direct-to-physician marketing on opioid prescribing. Health Aff (Millwood). 2020;39:1002-1010. [PMID: 32479218]  doi: 10.1377/hlthaff.2019.01289
86.
Eloy JASvider PFBobian Met al. Industry relationships are associated with performing a greater number of sinus balloon dilation procedures. Int Forum Allergy Rhinol. 2017;7:878-883. [PMID: 28665550]  doi: 10.1002/alr.21976
87.
Fleischman WAgrawal SKing Met al. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ. 2016;354:i4189. [PMID: 27540015]  doi: 10.1136/bmj.i4189
88.
Freemantle NJohnson RDennis Jet al. Sleeping with the enemy? A randomized controlled trial of a collaborative health authority/industry intervention to influence prescribing practice. Br J Clin Pharmacol. 2000;49:174-9. [PMID: 10671913]
89.
Fujiwara RJTShih AFMehra S. Cross-sectional analysis of the relationship between paranasal sinus balloon catheter dilations and industry payments among otolaryngologists. Otolaryngol Head Neck Surg. 2017;157:880-886. [PMID: 28895455]  doi: 10.1177/0194599817728897
90.
Glass HE. Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior? Dis Manag. 2004;7:77-87. [PMID: 15035835]
91.
Gonzalez-Campoy JM. The physician-industry relationship: lessons from the Minnesota experience. Endocr Pract. 2009;15:292-7. [PMID: 19502208]
92.
Guo TSriram SManchanda P. “Let the Sunshine in”: the impact of industry payment disclosure on physician prescription behavior. Marketing Science. 2020;39:516-39.  doi: 10.1287/mksc.2019.1181
93.
Hadland SERivera-Aguirre AMarshall BDLet al. Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses. JAMA Netw Open. 2019;2:e186007. [PMID: 30657529]  doi: 10.1001/jamanetworkopen.2018.6007
94.
Hadland SECerdá MEarlywine JJet al. Analysis of pharmaceutical industry marketing of stimulants, 2014 through 2018. JAMA Pediatr. 2020;174:385-387. [PMID: 31961384]  doi: 10.1001/jamapediatrics.2019.5526
95.
Hoffman MN. Pharmaceutical detailing is not for everyone: side effects may include sub-optimal prescribing decisions, compromised patient health, and increased prescription drug spending. J Leg Med. 2012;33:381-97. [PMID: 22991956]
96.
Humphreys H. Conflicts of interest for medical practitioners [Letter]. J R Coll Physicians Edinb. 2020;50:92-95. [PMID: 32539049]  doi: 10.4997/JRCPE.2020.124
97.
Ichikawa IClayton EW. Doping doctors: the influence of the marketing departments of pharmaceutical companies on physician and researcher behavior in Japan. Account Res. 2016;23:245-53. [PMID: 26829657]  doi: 10.1080/08989621.2016.1144478
98.
Khan R, Nugent CM, Scaffidi MA, et al. Association of biologic prescribing for inflammatory bowel disease with industry payments to physicians [Abstract]. Gastroenterology. 2019;156(Suppl 1):S-606-7. Digestive Disease Week, San Diego, California, 18–21 May 2019. Abstract no. Su1776. doi: 10.1016/S0016-5085(19)38413-6
99.
Lee AJBandari JMacleod LCet al. Concentration of opioid-related industry payments in opioid crisis areas. J Gen Intern Med. 2019;34:187-189. [PMID: 30402818]  doi: 10.1007/s11606-018-4700-7
100.
Lee A, Ayyash O, Maganty A, et al. Pharmaceutical payments for opioids significantly favor extended-release medication and correlate with physician prescriptions [Abstract]. J Urol. 2019;201(Suppl):e420-1. American Association of Urology Annual Meeting, Chicago, Illinois, 3–6 May 2019. Abstract no. MP29-18. doi: 10.1097/01.JU.0000557553.74866.5b
101.
Lee A, Ayyash O, Maganty A, et al. Key opinion leaders motivate increased prescriptions among their local physicians [Abstract]. J Urol. 2019;201(Suppl):e628. American Association of Urology Annual Meeting, Chicago, Illinois, 3–6 May 2019. Abstract no. MP44-03. doi: 10.1097/01.JU.0000556246.28185.d5
102.
Lichter PR. Physician-industry interactions and anti-vascular endothelial growth factor use among US ophthalmologists. JAMA Ophthalmol. 2016;134:903-4. [PMID: 27355873]  doi: 10.1001/jamaophthalmol.2016.1794
103.
Lo BGrady D. Payments to physicians: does the amount of money make a difference? JAMA. 2017;317:1719-1720. [PMID: 28464150]  doi: 10.1001/jama.2017.1872
104.
Marcum ZA, Chang CY, Barthold D, et al. Association between pharmaceutical industry payments to physicians and prescribing of branded memantine and donepezil combination [Abstract]. Value Health. 2020;23(Suppl 1):S272. International Society for Pharmacoeconomics and Outcomes 2020 Conference, 18–20 May 2020. Abstract no. PND69. doi: 10.1016/j.jval.2020.04.961
105.
Maruf M, Sidana A, Purnell S, et al. Medications for urologic malignancies in the Open Payments data: financial relationships between industry and urologists [Abstract]. J Clin Oncol. 2017;35(Suppl):74. 2017 Genitourinary Cancers Symposium, Orlando, Florida, 16–18 February 2017. Abstract no. 74. doi: 10.1200/JCO.2017.35.6_suppl.74
106.
Maruf MSidana AFleischman Wet al. Financial relationships between urologists and industry: an analysis of Open Payments data. Urol Pract. 2018;5:180-6.  doi: 10.1016/j.urpr.2017.03.012
107.
McCarthy M. Doctors who take company cash are more likely to prescribe brand name drugs, analysis finds. BMJ. 2016;352:i1645. [PMID: 27000964]  doi: 10.1136/bmj.i1645
108.
Mitchell AP, Winn A, Dusetzina S. Pharmaceutical industry payments and oncologist drug selection [Abstract]. J Clin Oncol. 2017;35(Suppl):6510. 2017 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2–6 June 2017. Abstract no. 6510. doi: 10.1200/JCO.2017.35.15_suppl.6510
109.
Mitchell AP, Winn A, Lund JL, et al. Duration of physician-industry relationships and prescribing changes in oncology [Abstract]. J Clin Oncol. 2018;36(Suppl):6607. 2018 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 1–5 June 2018. Abstract no. 6607. doi: 10.1200/JCO.2018.36.15_suppl.6607
110.
Modi P, Ingham M, Singer E, et al. Pharmaceutical industry payments and physician prescribing of urologic drugs [Abstract]. J Urol. 2017;197(Suppl):e929. American Association of Urology Annual Meeting, Boston, Massachusetts, 12–16 May 2017. Abstract no. MP69-08. doi: 10.1016/j.juro.2017.02.2304
111.
Nalleballe KVeerapaneni KDHarada Yet al. Trends of industry payments in neurology subspecialties. Cureus. 2020;12:e9492. [PMID: 32879816]  doi: 10.7759/cureus.9492
112.
Olch DI. Conflict of interest and physician dispensing. Internist. 1987;28:13-6, 24. [PMID: 10284543]
113.
Pham-Kanter GAlexander GCNair K. Effect of physician payment disclosure laws on prescribing [Letter]. Arch Intern Med. 2012;172:819-21. [PMID: 22636826]  doi: 10.1001/archinternmed.2012.1210
114.
Forum. Drug company gifts to GPs may influence prescribing. Pharm Med. 2020;34:66-7.  doi: 10.1007/s40290-019-00321-z
115.
Gifts to doctors wield undue influence in France. Prescrire Int. 2020;29:135.
116.
Rampulla C. Relationships between physicians and industry. Rassegna di Patologia dell'Apparato Respiratorio. 2007;22:253-7.
117.
Rodwin MA. Medical commerce, physician entrepreneurialism, and conflicts of interest. Camb Q Healthc Ethics. 2007;16:387-97; discussion 439-42. [PMID: 18018918]
118.
Roehr B. Pharma gifts associated with higher number and cost of prescriptions written. BMJ. 2017;359:j4979. [PMID: 29074521]  doi: 10.1136/bmj.j4979
119.
Schofferman JBanja J. Conflicts of interest in pain medicine: practice patterns and relationships with industry. Pain. 2008;139:494-7. [PMID: 18814969]  doi: 10.1016/j.pain.2008.08.016
120.
Serhiyenko VRavishanker NVenkatesan R. Multi-stage multivariate modeling of temporal patterns in prescription counts for competing drugs in a therapeutic category. Appl Stoch Models Bus Ind. 2018;34:61-78.  doi: 10.1002/asmb.2232
121.
Seto B, Juarez D, Singh D. The relationship between pharmaceutical manufacturer funding and prescribing patterns for anticoagulants in the United States [Abstract]. J Manag Care Spec Pharm. 2015;21(Suppl):S55. Academy of Managed Care Pharmacy Nexus 2015, Orlando, Florida, 26–29 October 2015. Abstract no. I23. doi: 10.18553/jmcp.2015.21.10.S1
122.
Sharma M, Johnson ML, Vadhariya A, et al. The association of prescriber characteristics with prescriptions for proton pump inhibitors in the Medicare Part D beneficiaries [Abstract]. Value Health. 2016;19:A317. International Society for Pharmacoeconomics and Outcomes 21st Annual International Meeting, Washington, DC, 21–25 May 2016. Abstract no. PG129. doi: 10.1016/j.jval.2016.03.970
123.
Singh P, Adamson A, Mostaghimi A, et al. Impact of industry payments on prescribing patterns for TNF-alpha inhibitors among Medicare beneficiaries [Abstract]. J Invest Dermatol. 2018;138:B6. International Investigative Dermatology 2018 Meeting, Orlando, Florida, 16–19 May 2018. Abstract no. LB1499. doi: 10.1016/j.jid.2018.06.029
124.
Somai D, van Dijk L, Verheij R, et al. The effect of pharmaceutical marketing on the prescription of rofecoxib in Dutch general practice [Abstract]. Eur J Public Health. 2004;14(Suppl 1):70. 12th Annual European Public Health Association Meeting, Oslo, Norway, 7–9 October 2004. doi: 10.1093/eurpub/14.suppl_1.69
125.
Steinbrook R. Industry payments to physicians: lessons from orthopedic surgery. Comment on “Financial payments by orthopedic device makers to orthopedic surgeons”. Arch Intern Med. 2011;171:1765-6. [PMID: 22025435]  doi: 10.1001/archinternmed.2011.439
126.
Steinbrook R. Industry payments to physicians and prescribing of brand-name drugs. JAMA Intern Med. 2016;176:1123. [PMID: 27322808]  doi: 10.1001/jamainternmed.2016.2959
127.
Steinbrook R. Physicians, industry payments for food and beverages, and drug prescribing. JAMA. 2017;317:1753-1754. [PMID: 28464155]  doi: 10.1001/jama.2017.2477
128.
Steinbrook R. Industry payments and physician prescribing. JAMA Intern Med. 2019;179:1428-9. [PMID: 31282917]  doi: 10.1001/jamainternmed.2019.1081
129.
Taylor RGiles J. Cash interests taint drug advice. Nature. 2005;437:1070-1. [PMID: 16237402]
130.
Tsai HJ. Physician-industry interactions: there is no such thing as a free lunch [Letter]. Taiwan J Obstet Gynecol. 2008;47:252-5. [PMID: 18603524]  doi: 10.1016/S1028-4559(08)60098-4
131.
Vogel L. Pharma freebies for doctors linked to opioid prescribing habits. CMAJ. 2019;191:E202. [PMID: 30782649]  doi: 10.1503/cmaj.109-5713
132.
Yeh JS, Franklin JM, Avorn J, et al. Association of physicians' financial relationships with pharmaceutical companies and their lipid-lowering medication prescribing patterns [Abstract]. J Gen Intern Med. 2015;30(Suppl 2):S106. 38th Annual Meeting of the Society of General Internal Medicine, Toronto, Ontario, Canada, 22–25 April 2015. doi: 10.1007/s11606-015-3271-0
133.
Bandari JAyyash OMTurner RM 2ndet al. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide. Cancer. 2017;123:4356-4362. [PMID: 28749536]  doi: 10.1002/cncr.30914
134.
Chua KJLi GStahl PJet al. Receiving industry payments is associated with prescribing habits of tadalafil. Urol Pract. 2019;6:282-8.  doi: 10.1097/UPJ.0000000000000017
135.
Nguyen TAndraka-Christou BSimon Ket al. Provider-directed marketing may increase prescribing of medications for opioid use disorder. J Subst Abuse Treat. 2019;104:104-115. [PMID: 31370974]  doi: 10.1016/j.jsat.2019.06.014
136.
Nguyen TDBradford WDSimon KI. Pharmaceutical payments to physicians may increase prescribing for opioids. Addiction. 2019;114:1051-1059. [PMID: 30667135]  doi: 10.1111/add.14509
137.
Perlis RHPerlis CS. Physician payments from industry are associated with greater Medicare Part D prescribing costs. PLoS One. 2016;11:e0155474. [PMID: 27183221]  doi: 10.1371/journal.pone.0155474
138.
Wood SFPodrasky JMcMonagle MAet al. Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia. PLoS One. 2017;12:e0186060. [PMID: 29069085]  doi: 10.1371/journal.pone.0186060
139.
Yeh JSFranklin JMAvorn Jet al. Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts. JAMA Intern Med. 2016;176:763-8. [PMID: 27159336]  doi: 10.1001/jamainternmed.2016.1709

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 174Number 3March 2021
Pages: 353 - 361

History

Published online: 24 November 2020
Published in issue: March 2021

Keywords

Authors

Affiliations

Aaron P. Mitchell, MD, MPH https://orcid.org/0000-0003-3639-3515
Memorial Sloan Kettering Cancer Center, New York, New York (A.P.M., N.U.T., R.L.G., S.C., S.M.T., L.A.D., D.K.)
Memorial Sloan Kettering Cancer Center, New York, New York (A.P.M., N.U.T., R.L.G., S.C., S.M.T., L.A.D., D.K.)
Renee L. Gennarelli, MS https://orcid.org/0000-0003-2059-7265
Memorial Sloan Kettering Cancer Center, New York, New York (A.P.M., N.U.T., R.L.G., S.C., S.M.T., L.A.D., D.K.)
Memorial Sloan Kettering Cancer Center, New York, New York (A.P.M., N.U.T., R.L.G., S.C., S.M.T., L.A.D., D.K.)
Memorial Sloan Kettering Cancer Center, New York, New York (A.P.M., N.U.T., R.L.G., S.C., S.M.T., L.A.D., D.K.)
Johanna Goldberg, MSLIS https://orcid.org/0000-0003-1913-4722
Medical Library, Memorial Sloan Kettering Cancer Center, New York, New York (J.G.)
Memorial Sloan Kettering Cancer Center, New York, New York (A.P.M., N.U.T., R.L.G., S.C., S.M.T., L.A.D., D.K.)
Deborah Korenstein, MD
Memorial Sloan Kettering Cancer Center, New York, New York (A.P.M., N.U.T., R.L.G., S.C., S.M.T., L.A.D., D.K.)
Grant Support: By Memorial Sloan Kettering Cancer Center Support Grant P30 CA008748 from the National Cancer Institute.
Reproducible Research Statement: Study protocol: See the Supplement. Statistical code and data set: Not applicable.
Corresponding Author: Aaron P. Mitchell, MD, MPH, Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, NY 10017; e-mail, [email protected].
Current Author Addresses: Drs. Mitchell, Chimonas, and Korenstein; Ms. Trivedi; Ms. Gennarelli; and Ms. Tabatabai: Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, NY 10017.
Ms. Goldberg: Medical Library, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065.
Dr. Diaz: Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065.
Author Contributions: Conception and design: A.P. Mitchell, R.L. Gennarelli, S. Chimonas, L.A. Diaz Jr., D. Korenstein.
Analysis and interpretation of the data: A.P. Mitchell, R.L. Gennarelli, S. Chimonas, D. Korenstein.
Drafting of the article: A.P. Mitchell, N.U. Trivedi.
Critical revision of the article for important intellectual content: A.P. Mitchell, S. Chimonas, L.A. Diaz Jr., D. Korenstein.
Final approval of the article: A.P. Mitchell, N.U. Trivedi, R.L. Gennarelli, S. Chimonas, S.M. Tabatabai, J. Goldberg, L.A. Diaz Jr., D. Korenstein.
Statistical expertise: R.L. Gennarelli.
Administrative, technical, or logistic support: A.P. Mitchell, N.U. Trivedi, R.L. Gennarelli.
Collection and assembly of data: A.P. Mitchell, N.U. Trivedi, R.L. Gennarelli, S. Chimonas, S.M. Tabatabai, J. Goldberg, D. Korenstein.
This article was published at Annals.org on 24 November 2020.

Metrics & Citations

Metrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Aaron P. Mitchell, Niti U. Trivedi, Renee L. Gennarelli, et al. Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing?: A Systematic Review. Ann Intern Med.2021;174:353-361. [Epub 24 November 2020]. doi:10.7326/M20-5665

View More

Get Access

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/ePub

View PDF/ePub

Related in ACP Journals

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media